Listed

Summit Therapeutics Inc.

SMMTNasdaqCIK 1599298HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2024
Operating income−$65.6m, Q4 FY2024
Net income−$215.7m, Q2 FY2026
Summit Therapeutics Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-24, accession 0001599298-25-000048. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-24, accession 0001599298-25-000048. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m15.3Research and development, Q3 FY2023, three months to 2023-09-30$15.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2023-11-07, accession 0001599298-23-000098.Report this figure24.8Research and development, Q4 FY2023, three months to 2023-12-31$24.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2024-02-20, accession 0001599298-24-000031. Derived: 12-month figure less the 9-month figure.Report this figure30.9Research and development, Q1 FY2024, three months to 2024-03-31$30.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-05-01, accession 0001599298-24-000085.Report this figurenot reportednot reportednot reported51.3Research and development, Q1 FY2025, three months to 2025-03-31$51.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure208Research and development, Q2 FY2025, three months to 2025-06-30$208.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figurenot reportednot reported133Research and development, Q1 FY2026, three months to 2026-03-31$132.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure158Research and development, Q2 FY2026, three months to 2026-06-30$157.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure
Operating income$m(20.5)Operating income, Q3 FY2023, three months to 2023-09-30−$20.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figure(36.2)Operating income, Q4 FY2023, three months to 2023-12-31−$36.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-24, accession 0001599298-25-000048. Derived: 12-month figure less the 9-month figure.Report this figure(42.4)Operating income, Q1 FY2024, three months to 2024-03-31−$42.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-05-01, accession 0001599298-24-000085.Report this figure(59.6)Operating income, Q2 FY2024, three months to 2024-06-30−$59.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-08-06, accession 0001599298-24-000117.Report this figure(58.4)Operating income, Q3 FY2024, three months to 2024-09-30−$58.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figure(65.6)Operating income, Q4 FY2024, three months to 2024-12-31−$65.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-24, accession 0001599298-25-000048. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported
Interest expense$mnot reportednot reported3.1Interest expense, Q1 FY2024, three months to 2024-03-31$3.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure3.1Interest expense, Q2 FY2024, three months to 2024-06-30$3.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-11, accession 0001599298-25-000126.Report this figure2.5Interest expense, Q3 FY2024, three months to 2024-09-30$2.5m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure0.0Interest expense, Q4 FY2024, three months to 2024-12-31$9.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-23, accession 0001599298-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-11, accession 0001599298-25-000126.Report this figure0.0Interest expense, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure0.0Interest expense, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-23, accession 0001599298-26-000015. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(21.3)Net income, Q3 FY2023, three months to 2023-09-30−$21.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figure(36.6)Net income, Q4 FY2023, three months to 2023-12-31−$36.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-23, accession 0001599298-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure(43.5)Net income, Q1 FY2024, three months to 2024-03-31−$43.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure(60.4)Net income, Q2 FY2024, three months to 2024-06-30−$60.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure(56.3)Net income, Q3 FY2024, three months to 2024-09-30−$56.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure(61.2)Net income, Q4 FY2024, three months to 2024-12-31−$61.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-23, accession 0001599298-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure(62.9)Net income, Q1 FY2025, three months to 2025-03-31−$62.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure(566)Net income, Q2 FY2025, three months to 2025-06-30−$565.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure(232)Net income, Q3 FY2025, three months to 2025-09-30−$231.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure(219)Net income, Q4 FY2025, three months to 2025-12-31−$219.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-23, accession 0001599298-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure(189)Net income, Q1 FY2026, three months to 2026-03-31−$189.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure(216)Net income, Q2 FY2026, three months to 2026-06-30−$215.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure
Diluted EPS$ per share(0.03)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figurenot reported(0.06)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure(0.09)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0001599298-25-000126.Report this figure(0.08)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figurenot reported(0.09)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure(0.76)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.76 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure(0.31)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figurenot reported(0.24)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure(0.28)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure
Basic EPS$ per share(0.03)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figurenot reported(0.06)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure(0.09)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0001599298-25-000126.Report this figure(0.08)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figurenot reported(0.09)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure(0.76)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.76 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure(0.31)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figurenot reported(0.24)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure(0.28)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure

Balance sheet

Cash and equivalents$419.4m, Q2 FY2026
Shareholders' equity$630.0m, Q2 FY2026
Summit Therapeutics Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m23.8Cash and equivalents, Q3 FY2023, at 2023-09-30$23.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-07, accession 0001599298-23-000098.Report this figure71.4Cash and equivalents, FY2023, at 2023-12-31$71.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-23, accession 0001599298-26-000015.Report this figure61.3Cash and equivalents, Q1 FY2024, at 2024-03-31$61.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure28.4Cash and equivalents, Q2 FY2024, at 2024-06-30$28.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0001599298-25-000126.Report this figure93.8Cash and equivalents, Q3 FY2024, at 2024-09-30$93.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure105Cash and equivalents, FY2024, at 2024-12-31$104.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-23, accession 0001599298-26-000015.Report this figure212Cash and equivalents, Q1 FY2025, at 2025-03-31$211.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure298Cash and equivalents, Q2 FY2025, at 2025-06-30$297.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure239Cash and equivalents, Q3 FY2025, at 2025-09-30$238.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure225Cash and equivalents, FY2025, at 2025-12-31$225.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure107Cash and equivalents, Q1 FY2026, at 2026-03-31$106.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure419Cash and equivalents, Q2 FY2026, at 2026-06-30$419.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure
Current assets$m205Current assets, Q3 FY2023, at 2023-09-30$205.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-07, accession 0001599298-23-000098.Report this figure190Current assets, FY2023, at 2023-12-31$189.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-24, accession 0001599298-25-000048.Report this figure163Current assets, Q1 FY2024, at 2024-03-31$163.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-01, accession 0001599298-24-000085.Report this figure329Current assets, Q2 FY2024, at 2024-06-30$328.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0001599298-24-000117.Report this figure490Current assets, Q3 FY2024, at 2024-09-30$490.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figure424Current assets, FY2024, at 2024-12-31$423.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-23, accession 0001599298-26-000015.Report this figure371Current assets, Q1 FY2025, at 2025-03-31$370.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure309Current assets, Q2 FY2025, at 2025-06-30$309.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0001599298-25-000126.Report this figure246Current assets, Q3 FY2025, at 2025-09-30$246.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure720Current assets, FY2025, at 2025-12-31$720.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure617Current assets, Q1 FY2026, at 2026-03-31$616.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure721Current assets, Q2 FY2026, at 2026-06-30$720.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure
Total assets$m218Total assets, Q3 FY2023, at 2023-09-30$218.5m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-07, accession 0001599298-23-000098.Report this figure203Total assets, FY2023, at 2023-12-31$202.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-24, accession 0001599298-25-000048.Report this figure177Total assets, Q1 FY2024, at 2024-03-31$176.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-01, accession 0001599298-24-000085.Report this figure342Total assets, Q2 FY2024, at 2024-06-30$341.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0001599298-24-000117.Report this figure503Total assets, Q3 FY2024, at 2024-09-30$502.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figure436Total assets, FY2024, at 2024-12-31$435.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-23, accession 0001599298-26-000015.Report this figure384Total assets, Q1 FY2025, at 2025-03-31$383.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure324Total assets, Q2 FY2025, at 2025-06-30$324.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0001599298-25-000126.Report this figure262Total assets, Q3 FY2025, at 2025-09-30$261.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure751Total assets, FY2025, at 2025-12-31$751.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure648Total assets, Q1 FY2026, at 2026-03-31$647.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure752Total assets, Q2 FY2026, at 2026-06-30$752.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure
Current liabilities$m114Current liabilities, Q3 FY2023, at 2023-09-30$113.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-07, accession 0001599298-23-000098.Report this figure20.4Current liabilities, FY2023, at 2023-12-31$20.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-24, accession 0001599298-25-000048.Report this figure23.4Current liabilities, Q1 FY2024, at 2024-03-31$23.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-01, accession 0001599298-24-000085.Report this figure140Current liabilities, Q2 FY2024, at 2024-06-30$140.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0001599298-24-000117.Report this figure59.0Current liabilities, Q3 FY2024, at 2024-09-30$59.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figure41.7Current liabilities, FY2024, at 2024-12-31$41.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-23, accession 0001599298-26-000015.Report this figure34.9Current liabilities, Q1 FY2025, at 2025-03-31$34.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure60.3Current liabilities, Q2 FY2025, at 2025-06-30$60.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0001599298-25-000126.Report this figure64.9Current liabilities, Q3 FY2025, at 2025-09-30$64.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure73.0Current liabilities, FY2025, at 2025-12-31$73.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure83.3Current liabilities, Q1 FY2026, at 2026-03-31$83.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure104Current liabilities, Q2 FY2026, at 2026-06-30$103.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure
Total liabilities$m119Total liabilities, Q3 FY2023, at 2023-09-30$119.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-07, accession 0001599298-23-000098.Report this figure125Total liabilities, FY2023, at 2023-12-31$125.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-24, accession 0001599298-25-000048.Report this figure133Total liabilities, Q1 FY2024, at 2024-03-31$132.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-01, accession 0001599298-24-000085.Report this figure147Total liabilities, Q2 FY2024, at 2024-06-30$146.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0001599298-24-000117.Report this figure64.9Total liabilities, Q3 FY2024, at 2024-09-30$64.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figure46.8Total liabilities, FY2024, at 2024-12-31$46.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-23, accession 0001599298-26-000015.Report this figure39.5Total liabilities, Q1 FY2025, at 2025-03-31$39.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure64.6Total liabilities, Q2 FY2025, at 2025-06-30$64.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0001599298-25-000126.Report this figure69.5Total liabilities, Q3 FY2025, at 2025-09-30$69.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure92.3Total liabilities, FY2025, at 2025-12-31$92.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure102Total liabilities, Q1 FY2026, at 2026-03-31$101.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure122Total liabilities, Q2 FY2026, at 2026-06-30$122.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure
Shareholders' equity$m99.4Shareholders' equity, Q3 FY2023, at 2023-09-30$99.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figure77.7Shareholders' equity, FY2023, at 2023-12-31$77.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-23, accession 0001599298-26-000015.Report this figure44.2Shareholders' equity, Q1 FY2024, at 2024-03-31$44.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure195Shareholders' equity, Q2 FY2024, at 2024-06-30$195.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure438Shareholders' equity, Q3 FY2024, at 2024-09-30$437.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure389Shareholders' equity, FY2024, at 2024-12-31$388.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure344Shareholders' equity, Q1 FY2025, at 2025-03-31$344.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure259Shareholders' equity, Q2 FY2025, at 2025-06-30$259.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure192Shareholders' equity, Q3 FY2025, at 2025-09-30$192.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure659Shareholders' equity, FY2025, at 2025-12-31$658.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure546Shareholders' equity, Q1 FY2026, at 2026-03-31$545.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure630Shareholders' equity, Q2 FY2026, at 2026-06-30$630.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure

Cash flow

Operating cash flow−$141.1m, Q2 FY2026
Capital expenditure$909.0k, Q2 FY2026
Summit Therapeutics Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(14.9)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$14.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-10-30, accession 0001599298-24-000158. Derived: 9-month figure less the 6-month figure.Report this figure(19.5)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$19.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-23, accession 0001599298-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure(30.1)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$30.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure(33.0)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$33.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0001599298-25-000126. Derived: 6-month figure less the 3-month figure.Report this figure(30.3)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$30.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-20, accession 0001599298-25-000159. Derived: 9-month figure less the 6-month figure.Report this figure(48.7)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$48.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-23, accession 0001599298-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure(61.2)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$61.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure(66.7)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$66.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-23, accession 0001599298-26-000068. Derived: 6-month figure less the 3-month figure.Report this figure(93.1)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$93.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-20, accession 0001599298-25-000159. Derived: 9-month figure less the 6-month figure.Report this figure(102)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$101.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-23, accession 0001599298-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure(122)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$122.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure(141)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$141.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-23, accession 0001599298-26-000068. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.1Capital expenditure, Q3 FY2023, three months to 2023-09-30$53.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-10-30, accession 0001599298-24-000158. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-23, accession 0001599298-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure0.1Capital expenditure, Q2 FY2024, three months to 2024-06-30$63.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0001599298-25-000126. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2024, three months to 2024-09-30$58.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-20, accession 0001599298-25-000159. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-23, accession 0001599298-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure0.4Capital expenditure, Q1 FY2025, three months to 2025-03-31$422.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-23, accession 0001599298-26-000068. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$71.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-20, accession 0001599298-25-000159. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2025, three months to 2025-12-31$164.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-23, accession 0001599298-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2026, three months to 2026-03-31$245.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure0.9Capital expenditure, Q2 FY2026, three months to 2026-06-30$909.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-23, accession 0001599298-26-000068. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)778.18m, Q2 FY2026
Summit Therapeutics Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares209Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30208,909,351 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-07, accession 0001599298-23-000098.Report this figure378Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31378,163,980 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-01, accession 0001599298-24-000085.Report this figure698Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30697,685,365 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0001599298-24-000117.Report this figure698Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30697,739,477 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-10-30, accession 0001599298-24-000158.Report this figure702Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31701,785,250 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-01, accession 0001599298-25-000089.Report this figure708Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30707,904,643 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0001599298-25-000126.Report this figure727Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30726,656,045 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure738Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31738,076,003 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure743Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30742,615,007 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure743Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30743,415,917 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-10-20, accession 0001599298-25-000159.Report this figure775Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31775,458,141 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-04-30, accession 0001599298-26-000039.Report this figure778Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30778,184,568 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure

Shares outstanding: 797.75mShares outstanding, period not labelled, at 2026-07-17797,749,602 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-07-23, accession 0001599298-26-000068.Report this figure at Jul 17, 2026, from the cover of the 10-Q filed Jul 23, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.